Lithium (Li + ), a mood stabilizer, has profound effects on cultured neurons, offering an opportunity to investigate its cellular biological effects. Here we consider the effect of Li + and other psychotropic drugs on growth cone morphology and chemotaxis. Li + inhibits GSK-3 (glycogen synthase kinase-3) at a therapeutically relevant concentration. Treated cells show a number of features that arise due to GSK-3 inhibition, such as altered microtubule dynamics, axonal branching and loss of semaphorin 3A-mediated growth cone collapse. Li + also causes growth cones to spread; however, a similar effect is seen with two other mood stabilizers, valproic acid and carbamazepine, but without changes in microtubules or axon branching. This common effect of mood stabilizers is mediated by changes in inositol phosphate signalling, not GSK-3 activity. Given the presence of neurogenesis in the adult brain, we speculate that changes in growth cone behaviour could also occur during treatment of mental disorders.
Introduction
Lithium (Li + ) was first used as a mood stabilizer in the nineteenth century, and was then rediscovered in 1949 by John Cade [1] . It is an effective treatment for both acute and long-term phases of manic depression (more properly known as bipolar mood disorder). Although clearly beneficial, Li + treatment is not without problems, including potentially serious side effects and individuals who fail to respond [2] . Probably, the major barriers to improved drug therapy are our lack of a molecular mechanism for Li + treatment and our poor understanding of the origins of this disorder. The action of Li + may be considered at many levels, but here we describe our attempts to understand the effects of Li + and other mood stabilizers on neuronal cell biology.
Lithium, GSK-3 (glycogen synthase kinase-3) and neuroprotection
There are two GSK-3 genes (GSK-3α and GSK-3β) in vertebrates [3] . All appear to be inhibited by Li + in vitro and in vivo [4, 5] . Enzyme kinetic experiments suggest that this is through competition for Mg 2+ binding at a site distinct from the ATP-binding site [6, 7] . The K i for GSK-3β is 2.0 mM, whereas it appears to be a little higher for GSK-3α. However, reducing the Mg 2+ concentration to 0.75 mM, approximately that of the free Mg 2+ concentration in cells, decreases the IC 50 to 0.8 mM, well within the therapeutic range of 0.6-1.2 mM.
Li
+ is a neuroprotectant, an effect that may be attributed to its inhibition of GSK-3 [8, 9] . For example, Aβ (β-amyloid protein) of rat hippocampal neurons both increases GSK-3β expression and induces apoptosis; an effect that is blocked by antisense oligonucleotides directed at GSK-3 [10] . Addition of Aβ peptide to hippocampal cells also leads to a decrease in cytosolic β-catenin. This is reversed by addition of Wnt3a or Li + treatment, and both protect against neurotoxicity [11] .
Growth cones and the cytoskeleton
Ramon y Cajal [12] concluded that the growth cones at the ends of developing axons are 'endowed with amoeboid movements' that respond to chemical signals. These motile growth cones are responsible for the pattern of axonal and dendritic processes as they extend from the neuronal cell body. Through their response to guidance cues, growth cones steer the developing axons and dendrites to their targets, where they develop into the synapse. Growth cone motility requires both F-actin (filamentous actin) and microtubule cytoskeleton [13] . Growth cones steer by localized assembly of these cytoskeletal elements [14, 15] . Actin polymerization at the periphery drives protrusion of the leading edge of the growth cone [16] , and traction is achieved by points of adhesion between actin filaments and the extracellular matrix. Attractive guidance signals promote local actin polymerization, and repellent signals induce its local collapse. As the growth cone moves forward, F-actin flows from the periphery towards the centre of the growth cone, where it disassembles to be recycled to the leading edge for further growth.
Stable microtubules form the major structural component of the axon, but as they project from the end of the axon into the growth cone they become much more dynamic, and exhibit a highly complex behaviour, splaying, bending and projecting in different directions [17] . Changes in microtubule structure appear to be responsible for branching along the axon, although this also involves changes in the actin cytoskeleton [18] . Li + and Wnt proteins alter growth cone morphology, axonal branching and microtubule organization [19] , an effect also seen with the specific GSK-3 inhibitors SB216763 and SB415286 [20] . These results suggest that Wnt signalling may regulate the microtubule cytoskeleton of developing neurons through inhibition of GSK-3 activity (see the article by Goold and Gordon-Weeks [20a] ).
Lithium, GSK-3 and growth cone collapse
Not all effects of GSK3 inhibition on the neuronal cytoskeleton appear to involve microtubules. Sema3A (semaphorin 3A) is a repulsive signal that steers the growth cone away from the source. When applied uniformly, Sema3A induces a rapid collapse of the entire growth cone. This effect is blocked in the presence of Li + or the GSK-3 inhibitors SB216763 and SB415286 [21] . To further verify that this is a specific GSK-3-mediated event, we used a peptide inhibitor based on a GSK-3 pseudosubstrate; this has both specificity and high affinity for GSK-3 (W.J. Ryves and A.J. Harwood, unpublished work). As seen for Li + , SB216763 and SB415286, this peptide inhibitor also blocked Sema3A-induced collapse of growth cones.
One mechanism for regulation of GSK-3 is phosphorylation at the N-terminus (position Ser-21 in GSK-3α and Ser-9 in GSK-3β). A pool of phosphorylated, and hence inactive, GSK-3 co-localizes with F-actin at the leading edge of the growth cones. Sema3A induces a rapid loss of this phosphorylation, and hence GSK-3 activation [21] . The mechanism of Sema3A action is unclear. Inhibitors of PI3K (phosphoinositide 3-kinase) reduce Ser-9 phosphorylation of GSK-3 in the periphery and alter growth cone morphology, but do not cause growth cone collapse. This suggests that PI3K, and hence PKB (protein kinase B), are involved in keeping GSK-3 in its inactive state, and presents a possible link to other chemotactic functions of PI3K observed at the leading edge of motile cells [22] .
Growth cones spreading, lithium and other mood stabilizers
Migrating growth cones cycle between fast-moving forms, which have an elongated, contracted appearance and slowmoving, spread forms, which are rich in filopodia and lamellipodia [23, 24] . Spreading corresponds to periods of sensing and integration of guidance cues from the environment, and can precede a direction change [25] . The cycling between the contracted and spread forms, however, is independent of chemotaxis, and represents an underlying autonomous behaviour of motile growth cones. A similar periodic behaviour is seen in the chemotactic amoebae Dictyostelium [26] . As a consequence, when fixed and sampled at a single time point, neuronal growth cones show a range of sizes with an increase in the proportion of contracted forms being indicative of high rates of motility and reduced growth cone spreading (see Figure 1) . Li + causes a substantial increase in growth cone spreading, as is associated with reduced axon length [27, 28] . This is consistent with growth cones spending an increased time in the spread form, and hence moving more slowly. As described above, the microtubules of Li + -treated growth cones extend into the enlarged growth cone, and take on a characteristic curled morphology [29] . This raises the question of whether the change in growth cone behaviour is a consequence of the altered microtubule dynamics resulting from GSK-3 inhibition.
Valproic acid (VPA) and carbamazepine (CBZ) are both mood stabilizers, and can be used to replace or augment Li + treatment. As seen for Li + , both drugs increase growth cone spreading [27, 28] . In addition, imprimine and chlorpromazine also increase growth cone spreading, but this is not seen with other anti-depressants, anti-psychotics or the anti-epileptic and mood stabilizer lamotrigine (G. Shaltiel, E. Dalton, R.H. Belmaker, A.J. Harwood and G. Agam, unpublished work). Importantly, neither VPA nor CBZ caused increased microtubule dynamics or induced axonal branching in our experiments [28] . In contrast, in a study by Hall et al. [31] , VPA appeared to have similar effects to that of Li + on microtubule dynamics. It is unclear why there should be such discrepancy; however, it may reflect differences in cell type, differentiation state and cell maturity. Despite these differences, these observations indicate that growth cone spreading is not simply a consequence of changes in microtubule dynamics, and the two processes can be uncoupled.
A number of further observations indicate that the process of growth cone spreading observed above does not arise through inhibition of GSK-3. First, despite an initial report to the contrary for VPA, neither it nor CBZ inhibit either GSK-3 isoform in vitro [32] . Secondly, some reports suggest that VPA may lead to altered PKB phosphorylation of GSK-3, and hence indirectly inhibit kinase activity [33] . Inositol is synthesized by isomerization of glucose 6-phosphate by the enzyme inositol synthase. This enzyme activity is inhibited by VPA. As both of these drugs deplete myo-inositol, their effects can be reversed by addition of exogenous myo-inositol. Finally, myo-inositol can be released by dephosphorylation of high-order inositol phosphates. This step is negatively regulated by PO, and hence inositol depletion can be reversed by inhibitors of this enzyme.
Using rat DRG (dorsal root ganglia) and cultured neocortical cells, both primary neuronal cells, we find no evidence for altered GSK-3 activity using tau phosphorylation as an in vivo substrate. Furthermore, the activity of GSK-3 extracted from drug-treated cells is unaltered, suggesting that no inhibitory modification of the GSK-3 proteins has occurred. Finally, we see no accumulation of β-catenin in DRG cells after VPA or CBZ treatment [28] . These biochemical observations argue against GSK-3 as a common target for mood stabilizers in primary neuronal cultures.
Mood stabilizers and inositol

Li
+ is an inhibitor of inositol monophosphatase, which is critical for recycling and de novo synthesis of inositol. Furthermore, VPA has recently been shown to inhibit inositol synthase [34, 35] . Therefore both drugs will lead to reduced concentrations of myo-inositol and hence attenuate inositol phosphate-based signalling (Figure 2 ). To test whether growth cone spreading is due to inositol depletion, DRG cells were treated with Li + , VPA or CBZ in the presence of myo-inositol. In all cases, inositol treatment reversed the effects of the drugs. To test further this possibility, DRG cells were treated with inhibitors of PO (prolyl oligopeptidase). Inhibition of PO has been shown in both Dictyostelium and astroglioma cells to elevate the cellular Ins(1,4,5)P 3 concentration [36, 37] . In Dictyostelium, ablation of the PO gene confers resistance to the effects of both Li + and VPA. PO inhibitors reverse the effect of all three mood stabilizers on DRG cells [28] . These observations indicate that an inositol phosphate signalling-based process is targeted by Li + , VPA and CBZ.
The mechanism by which inositol depletion causes an increase in growth cone size remains unknown. A range of complex growth cone chemotactic behaviours are associated with intracellular calcium release, a process mediated by Ins(1,4,5)P 3 [38, 39] : therefore a distinct possibility is that altered release of calcium from intracellular stores affects intracellular signalling, and is manifested as increased growth cone spreading. However, there are alternatives, such as changes in the inositol-containing PIPs (phosphatidylinositol phosphates; see Figure 2 ). Interestingly, decreasing the concentration of PIP 2 (phosphatidylinositol 4,5-bisphosphate) using an inactive phosphatidylinositol 4-phosphate 5-kinase antagonizes the effects of several guidance cues that induce growth cone collapse [40] . PIP 2 is the substrate for PI3K, and 3-phosphorylated PIPs are involved in chemotaxis in many eukaryotic cells [41] .
Lithium, bipolar mood disorder and growth cones
Berridge et al. [42] proposed inositol depletion as a mechanism for Li + action in the treatment of mood disorders, and numerous reports have identified altered inositol phosphate signalling in mood disorders [43] . The evidence presented here for VPA and CBZ lends further support to the idea that at least some mood stabilizers treat abnormal inositol phosphate signalling. Furthermore, abnormal plasma PO activity has been observed in untreated schizophrenia, unipolar and bipolar patients [44] , and a recent report found that euthymic bipolar patients treated with Li + had reduced plasma PO activity [45] . This would fit a model where alterations in plasma PO activity alter inositol phosphate signalling, which can be countered by lithium, VPA or CBZ treatment.
Could neuronal growth cones be a therapeutic target? The discovery of neurogenesis in the adult brain opens up some interesting possibilities. Neurogenesis, albeit at a low rate, has been reported in the adult brain of rodents, primates and in the human brain [46,47,47a] . A number of factors can increase hippocampal neurogenesis, at least in rodents and primates, such as increased exercise, environmental enrichment and learning [48, 49] . On the other hand, stress and high glucocorticoid levels reduce neurogenesis [50] . Furthermore, chronic treatment with the anti-depressant fluoxetine stimulates cell proliferation in the rat brain [51, 52] , and cell proliferation in the hippocampus is required for some of the behavioural effects of fluoxetine seen in mice [53] .
Although discussion in the literature has centred around the effects on cell number and survival, it is important also to consider that newly formed neurons in the mouse hippocampus possess functional morphological and electrophysiological interactions with the surrounding cells [54] . In addition to altering rates of neurogenesis, it is possible that psychotropic drugs could also alter subsequent neuronal development, and it is not hard to imagine the effect that even a subtle change in axonal branching or growth cone chemotaxis could have on the connectivity of the neural network. Such drug-induced alterations in the trajectory or branching of new neurons could then re-adjust or compensate for detrimental neural activity.
Concluding remarks
Li
+ and other mood stabilizers have significant effects on the behaviour of neurons in culture, including cell survival, morphology and chemotaxis. At least some of these effects are due to inhibition of GSK-3. However, this is not the case for all, and in common with the other mood stabilizers VPA and CBZ, Li + can alter growth cone behaviour through inositol depletion. These structural and chemotactic changes could even form part of the therapeutic effects of lithium if they also occur in the newly formed neurons of the adult brain. 
